Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies

[1]  Xin Pan,et al.  Novel strategy for immunomodulation: Dissolving microneedle array encapsulating thymopentin fabricated by modified two‐step molding technology , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Liang Yanfang,et al.  Thymopentin improves cardiac function in older patients with chronic heart failure , 2016, Anatolian journal of cardiology.

[3]  Y. Zou,et al.  Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[4]  F. Dorkoosh,et al.  Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Zhirong Zhang,et al.  A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides. , 2015, Biomaterials.

[6]  X. Ke,et al.  Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells in vitro. , 2015, Experimental cell research.

[7]  W. Ahmed,et al.  Thymopentin nanoparticles engineered with high loading efficiency, improved pharmacokinetic properties, and enhanced immunostimulating effect using soybean phospholipid and PHBHHx polymer. , 2014, Molecular pharmaceutics.

[8]  V. M. Komarov,et al.  Structural and dynamic properties of thymopoietin mimetics , 2014, Journal of biomolecular structure & dynamics.

[9]  Hyun-Jong Cho,et al.  A new injectable liquid crystal system for one month delivery of leuprolide. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Xun Sun,et al.  Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics. , 2013, Die Pharmazie.

[11]  Tao Gong,et al.  A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. , 2012, Biomaterials.

[12]  N. Garti,et al.  Interactions of surfactants in nonionic/anionic reverse hexagonal mesophases and solubilization of α-chymotrypsinogen A , 2011 .

[13]  G. Wei,et al.  Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants. , 2010, International journal of pharmaceutics.

[14]  Xun Sun,et al.  Inhalable Microparticles as Carriers for Pulmonary Delivery of Thymopentin-Loaded Solid Lipid Nanoparticles , 2010, Pharmaceutical Research.

[15]  Yourong Duan,et al.  Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels. , 2010, International journal of pharmaceutics.

[16]  M. Qiao,et al.  Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  M. Qiao,et al.  Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[18]  Qiang Zhang,et al.  Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague–Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers , 2005, Peptides.

[19]  Jian Wang,et al.  Measurement of subgroups of peripheral blood T lymphocytes in patients with severe acute respiratory syndrome and its clinical significance. , 2003, Chinese medical journal.

[20]  V. John,et al.  Microstructure determination of AOT + phenol organogels utilizing small-angle X-ray scattering and atomic force microscopy. , 2001, Journal of the American Chemical Society.

[21]  Spada,et al.  Decreased antioxidant defence in individuals infected by the human immunodeficiency virus , 2000, European journal of clinical investigation.

[22]  B. Bodey,et al.  Review of thymic hormones in cancer diagnosis and treatment. , 2000, International journal of immunopharmacology.

[23]  J. McPherson,et al.  Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. , 1999, Human gene therapy.

[24]  G. Folkers,et al.  Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action. , 1999, Pharmaceutica acta Helvetiae.

[25]  W. Haq,et al.  Thymopentin and splenopentin as immunomodulators , 1998, Immunologic research.

[26]  O. Schiraldi,et al.  Topical thymopentin therapy in HIV positive patients with recurrent oral candidiasis: a pilot study. , 1996, The new microbiologica.

[27]  E. Sundal,et al.  Thymopentin treatment of rheumatoid arthritis. , 1994, Arzneimittel-Forschung.

[28]  F. Biffoni,et al.  Use of thymopentin in autoimmune hemolytic anemia due to chronic lymphocytic leukemia , 1988 .

[29]  T. Audhya,et al.  Thymopentin: stability considerations and potency by various routes of administration , 1985, Survey of immunologic research.

[30]  T. Audhya,et al.  Thymopoietin to thymopentin: experimental studies , 1985, Survey of immunologic research.

[31]  T. Audhya,et al.  Thymopentin (TP-5) potency in vivo is enhanced by slow infusion. , 2009, International journal of peptide and protein research.

[32]  G. Goldstein,et al.  Short in vitro half-life of thymopoietin32--36 pentapeptide in human plasma. , 2009, International journal of peptide and protein research.